Latest Regulatory Approvals News

Page 9 of 390
Bathurst Resources lifted first-quarter consolidated EBITDA to NZ$9 million, helped by stronger export coal pricing and improved North Island domestic earnings. The miner held its FY27 EBITDA guidance at NZ$30 million to NZ$40 million while advancing two projects that could extend its operating life by up to 20 years.
Maxwell Dee
Maxwell Dee
30 Oct 2026
El Dorado Goldfields has begun testing a 180km² Guyana land package after securing an option to acquire a 90% interest in the Oko North and Oko South projects. Early rock-chip assays reached 2.32 g/t gold, but the greenfields projects remain undrilled and have no defined resources or reserves.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Cokal has resumed mining and hauling at its 60%-owned Bumi Barito Mineral project after delayed Indonesian regulatory approval, but exceptionally low Barito River levels have pushed the next shipment to a tentative mid-November date. The company also bought three years of extra time on BBM's US$20 million repayment, while quarter-end cash stood at just US$193,000.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Pinnacle Minerals is seeking shareholder approval for a securities-funded acquisition of five early-stage tungsten projects in Utah, alongside a proposed A$1.3 million placement. The transaction would bring new management, substantial exploration commitments and a sharply larger pool of performance securities.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Wide Open Agriculture has completed the major physical steps in exiting its German manufacturing facility and is now testing four prospective Asian production partners. The transition could lower fixed costs, but commercial supply still depends on technical trials, partner selection and a definitive agreement.
Victor Sage
Victor Sage
30 Oct 2026
Burley Minerals has confirmed shallow Channel Iron Deposit mineralisation across its Cane Bore North and Step-Out Targets, with assays reaching 52.7% iron. The exploration success comes alongside $725,000 in cash and an estimated 2.04 quarters of funding at current outgoings.
Maxwell Dee
Maxwell Dee
30 Oct 2026
OncoSil Medical enters FY27 with FDA approval for its cancer device, rising quarterly revenue and fresh institutional funding, but its U.S. opportunity still depends on reimbursement and a tightly controlled initial rollout. Cash rose to A$8.7 million after the capital raise, while operating cash use remained substantial.
Victor Sage
Victor Sage
30 Oct 2026
Bio-Gene Technology has moved closer to two commercialisation milestones, with Qcide product work progressing in Japan and a first Flavocide regulatory submission targeted for Q2 2027. The company ended September with A$2.103 million in cash, equivalent to an estimated 2.18 quarters of funding at the quarter’s operating cash rate.
Victor Sage
Victor Sage
30 Oct 2026
Algorae Pharmaceuticals has moved closer to its first expected NSW Health supply orders while reporting stronger preclinical results from its AOS2 drug-discovery platform. The company ended September with $3.15 million in cash and a further $3 million undrawn facility, but its commercial contract carries no minimum volume commitment.
Victor Sage
Victor Sage
30 Oct 2026
Capstone Copper delivered a record eighth consecutive quarter of adjusted EBITDA, while strong copper prices drove a sharp reduction in net debt. But production is now expected at the low end of 2026 guidance, costs at the high end and capital spending has risen by US$40 million.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Count has reported a strong start to FY2027, with first-quarter revenue up 23.2%, underlying EBITA up 66.6% and funds under management reaching $6.7 billion. The group is also pursuing a 30% stake in Brisbane accounting and advice firm Apiary, although the purchase price remains undisclosed and completion requires ACCC approval.
Claire Turing
Claire Turing
30 Oct 2026
Holista Colltech reported positive adjusted operating cash flow of A$318,000 for the September quarter, although statutory cash flow remained negative after its final ProImmune settlement payment. The company also pushed the planned start of its Collie collagen plant from December 2026 to May-July 2027, while ending the quarter with just A$23,000 in cash.
Victor Sage
Victor Sage
30 Oct 2026

Browse the archive

Full archive